Log in

ADVANZ PHARMA Stock Forecast, Price & News

0.00 (0.00 %)
(As of 12/2/2020 12:00 AM ET)
Today's Range
Now: $4.80
50-Day Range
MA: $4.64
52-Week Range
Now: $4.80
Volume5,051 shs
Average Volume20,185 shs
Market Capitalization$234.78 million
P/E RatioN/A
Dividend YieldN/A
ADVANZ PHARMA Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates in two segments, ADVANZ PHARMA International and ADVANZ PHARMA North America. The ADVANZ PHARMA International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies. This segment's products include Macrobid/Macrodantin to treat bladder infections, such as cystitis and urinary tract infections; Eltroxin, levothyroxine sodium that treats patients with an underactive thyroid gland; Fucithalmic, a topical gel treatment for patients suffering with a bacterial infection of the surface lining of the front of the eye; Zapain, a combination of codeine phosphate and paracetamol for severe pain reliefs, such as back pain, toothache, severe sprains and strains, and pain after operations. The ADVANZ PHARMA North America segment provides Donnatal, which is used as adjunctive therapy for irritable bowel syndrome; Zonegran, an anti-seizure drug indicated for adjunctive therapy in the treatment of partial seizures in adults with epilepsy; Nilandron for the treatment of metastatic prostate cancer; Plaquenil for the treatment of lupus and rheumatoid arthritis; and Photofrin for the treatment of certain types of cancer. The company sells its products through direct sales and local distribution relationships. The company was formerly known as Concordia International Corp. and changed its name to ADVANZ PHARMA Corp. in November 2018. ADVANZ PHARMA Corp. is headquartered in London, the United Kingdom.

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.46 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations



Sales & Book Value

Annual Sales$508.32 million
Book Value$0.31 per share


Net Income$-196,020,000.00


Market Cap$234.78 million
Next Earnings Date3/24/2021 (Estimated)
0.00 (0.00 %)
(As of 12/2/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CXRXF News and Ratings via Email

Sign-up to receive the latest news and ratings for CXRXF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

ADVANZ PHARMA (OTCMKTS:CXRXF) Frequently Asked Questions

How has ADVANZ PHARMA's stock been impacted by COVID-19 (Coronavirus)?

ADVANZ PHARMA's stock was trading at $3.59 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CXRXF stock has increased by 33.7% and is now trading at $4.80.
View which stocks have been most impacted by COVID-19

What stocks does MarketBeat like better than ADVANZ PHARMA?

Wall Street analysts have given ADVANZ PHARMA a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but ADVANZ PHARMA wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is ADVANZ PHARMA's next earnings date?

ADVANZ PHARMA is scheduled to release its next quarterly earnings announcement on Wednesday, March 24th 2021.
View our earnings forecast for ADVANZ PHARMA

Are investors shorting ADVANZ PHARMA?

ADVANZ PHARMA saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 800 shares, an increase of 14.3% from the October 31st total of 700 shares. Based on an average daily trading volume, of 9,300 shares, the short-interest ratio is presently 0.1 days.
View ADVANZ PHARMA's Short Interest

Who are some of ADVANZ PHARMA's key competitors?

Who are ADVANZ PHARMA's key executives?

ADVANZ PHARMA's management team includes the following people:
  • Mr. Graeme Neville Duncan, CEO & Director (Age 46, Pay $1.26M)
  • Mr. Adeel Ahmad, CFO & Interim Director (Age 46, Pay $752.73k)
  • Mr. Karl Ian Belk, Chief Operations Officer (Age 52, Pay $685.79k)
  • Mr. Robert Sully, Gen. Counsel (Age 47, Pay $669.75k)
  • Mr. Paul Burden, Chief Commercial Officer of Strategic Growth Unit (Age 45, Pay $638.96k)
  • Mr. Adam Peeler, VP of Investor Relations & Communications
  • Mr. Guy Clark, Chief Corp. Devel. Officer (Age 50)
  • Mr. Arijit Mookerjee, MD and CFO of CPI & CLI
  • Mr. Andrew Patrick Hoyt, Chief Financial Officer of US Bus.es
  • Mr. Robert D. Ford, MD & Sr. Director of Legal Affairs of CPI and CLI (Age 53)

What is ADVANZ PHARMA's stock symbol?

ADVANZ PHARMA trades on the OTCMKTS under the ticker symbol "CXRXF."

How do I buy shares of ADVANZ PHARMA?

Shares of CXRXF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ADVANZ PHARMA's stock price today?

One share of CXRXF stock can currently be purchased for approximately $4.80.

How big of a company is ADVANZ PHARMA?

ADVANZ PHARMA has a market capitalization of $234.78 million and generates $508.32 million in revenue each year. ADVANZ PHARMA employs 429 workers across the globe.

What is ADVANZ PHARMA's official website?

The official website for ADVANZ PHARMA is www.advanzpharma.com.

How can I contact ADVANZ PHARMA?

ADVANZ PHARMA's mailing address is 85 KING WILLIAM STREET, LONDON X0, EC4N 7BL. The company can be reached via phone at 44-20-8588-9100 or via email at [email protected]

This page was last updated on 12/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.